Final-Program-ATS-2023-AP.vp

SUNDAY • MAY 21

115

2:51 An Updated Interim Analysis of the Air Trial; an Open-label, Single-arm, 36-week, Phase 2 Trial of an Angiotensin Type 2 Receptor Agonist, C21, in Individuals With IPF/ R. Batta, Stockholm, Sweden 3:03 Randomized Proof-of-concept Study of AX-8, a TRPM8 Agonist, in Refractory or Unexplained Chronic Cough/ J. Smith, Manchester, United Kingdom 3:15 Response in Patient-reported Cough Severity in Soothe, a Phase 2b Trial of Camlipixant in Refractory Chronic Cough/ L. Mcgarvey, Belfast, United Kingdom 3:27 A Pilot Study Using a Novel Respiratory Wearable for Identifying Exacerbation Periods Remotely in High-risk Patients With Chronic Respiratory Diseases/ M.L. Chiu, Boston, MA 3:39 Predicting the Clinical Phenotype of COPD Patients Who May Benefit From Selective Pulmonary Vasodilator Therapy During Exercise: A Placebo-controlled Randomized Double-blind Cross-over Trial/ S.É. Collins, Edmonton, Canada 3:51 Data-Driven Clustering Identifies Idiopathic Pulmonary Fibrosis Endotypes With Prognostic Implications Using Tissue Turnover Biomarkers/ L. Egerod, Herlev, Denmark A101 LINKING BIOLOGY TO THE REAL WORLD IN ASTHMA AND ALLERGIC INFLAMMATION 2:15 p.m. - 4:15 p.m. Walter E. Washington Convention Center Room 201 (Level 2) Poster Viewing 2:15-3:00 Discussion 3:00-4:15 Chairing: J.G. Krings, MD, MSci, Saint Louis, MO M. Curtiss, MD, PhD, Birmingham, AL B.D. Medoff, MD, Boston, MA L. Rogers, MD, New York, NY 601 Mice Deficient in Glp1r Exhibit Increased Airway Resistance in a Model of Chronic Allergen-induced Airways Disease With Obesity/ M.D. Ihrie, Durham, NC 602 Targeting Reprogrammed Glycolysis in Aspergillus Fumigatus-activated Lung Eosinophils and Alveolar Macrophages for the Treatment of Severe Asthma/ P.X.L. Gan, Singapore, Singapore 603 Aspergillus Fumigatus Alkaline Protease 1 (Alp1) Controls Airway Smooth Muscle Functions in Asthma/ N.L. Pereira, Bethesda, MD BASIC • TRANSLATIONAL POSTER DISCUSSION SESSION

3:03 Unique Local Immune Gene Expression Signatures in Recall Responses of Individuals With Latent Tuberculosis Infection Following Bronchoscopic Challenge With Purified Protein Derivative (PPD)/ R.F. Silver, Cleveland, OH 3:15 Global Cell Free DNA Methylation in Pulmonary Tuberculosis Versus Latent Tuberculosis Infection/ C. Chang, Taipei, Taiwan 3:27 Disruption of 3ß-hydroxysteroid Dehydrogenase in Mycobacterium Tuberculosis Leads to Increased Virulence and Altered Inflammatory Response/ A.T. Roth, St. Louis, MO 3:39 Inhibiting PD-1 Restores Mycobacterium Tuberculosis Specific Poly-functional T Cells: Impact on Therapy of Drug Resistant Tuberculosis Patients/ D.K. Mitra, Delhi, India 3:51 Intradermal Immunization With Double Mutant Labile Toxin- Adjuvanted Antigen 85 Complex Promotes Mucosal Immunity Against Tuberculosis/ A. Meyer, New Orleans, LA Featured Speaker: 4:03 Host Directed Therapies for TB: Old and New/ W.R. Bishai, Baltimore, MD

BASIC • CLINICAL • TRANSLATIONAL MINI SYMPOSIUM

A99

CLINICAL TRIALS IN CHRONIC LUNG DISEASE

2:15 p.m. - 4:15 p.m.

Marriott Marquis Downtown Independence Ballroom Salons A-D (Level M4)

Chairing: M.G. Drake, MD, ATSF, Portland, OR V. Mock, MD, New York, NY K. Melamed, MD, Los Angeles, CA Oral Presentations: 2:15 Dupilumab Reduces Sputum Eosinophils, Mucus Plugging and Improves Ventilation in Patients With Moderate-to-Severe Asthma/ S. Svenningsen, Hamilton, Canada 2:27 Pulmonary Vascular Redistribution Following 2.5-years Anti-IL5-R a Treatment in Eosinophilic Asthma/ M. Mcintosh, London, Canada 2:39 Associations of a Plant Centered Diet and Lung Function Decline Across Early to Mid-adulthood: The Cardia Lung Study/ R. Wharton, New York, NY

ATS 2023 • Washington, DC